NeoGenomics Inc (NEO) stock
NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/3023% below fair value
$15.25−0.16 (-1.04%)
Close on Nov 17, 2026Market cap $1.97BP/E –Yield –
NeoGenomics r&d expenses
Research and development expenses are spending on new products and technology.
NeoGenomics's R&D Expenses for the twelve months ending Sep 30, 2026 was $39.33M, up 9.7% year over year. For fiscal 2025 it was $37.08M, up 19.0% from the year before. Over ten years it grew 24.3% a year on average. The highest annual figure on record is $37.08M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.08M | +19.0% |
| FY2024 | Dec 31, 2024 | $31.16M | +14.1% |
| FY2023 | Dec 31, 2023 | $27.31M | -9.9% |
| FY2022 | Dec 31, 2022 | $30.33M | +38.6% |
| FY2021 | Dec 31, 2021 | $21.87M | +165.8% |
| FY2020 | Dec 31, 2020 | $8.23M | -3.0% |
| FY2019 | Dec 31, 2019 | $8.49M | +182.8% |
| FY2018 | Dec 31, 2018 | $3.00M | -17.5% |
| FY2017 | Dec 31, 2017 | $3.64M | -21.8% |
| FY2016 | Dec 31, 2016 | $4.65M | +10.7% |
| FY2015 | Dec 31, 2015 | $4.20M | +56.1% |
| FY2014 | Dec 31, 2014 | $2.69M | +10.2% |
| FY2013 | Dec 31, 2013 | $2.44M | +7.0% |
| FY2012 | Dec 31, 2012 | $2.28M | +320.1% |
| FY2011 | Dec 31, 2011 | $543.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.86M | +13.4% |
| Q2 FY2026 | Jun 30, 2026 | $10.76M | +19.3% |
| Q1 FY2026 | Mar 31, 2026 | $9.53M | -6.4% |
| Q4 FY2025 | Dec 31, 2025 | $9.18M | +15.2% |
| Q3 FY2025 | Sep 30, 2025 | $8.69M | +13.1% |
| Q2 FY2025 | Jun 30, 2025 | $9.02M | +14.4% |
| Q1 FY2025 | Mar 31, 2025 | $10.18M | +33.6% |
| Q4 FY2024 | Dec 31, 2024 | $7.97M | +11.8% |
| Q3 FY2024 | Sep 30, 2024 | $7.68M | +45.4% |
| Q2 FY2024 | Jun 30, 2024 | $7.89M | +5.1% |
| Q1 FY2024 | Mar 31, 2024 | $7.62M | +3.0% |
| Q4 FY2023 | Dec 31, 2023 | $7.13M | +6.8% |
| Q3 FY2023 | Sep 30, 2023 | $5.29M | -27.7% |
| Q2 FY2023 | Jun 30, 2023 | $7.50M | -13.0% |
| Q1 FY2023 | Mar 31, 2023 | $7.40M | -4.1% |
| Q4 FY2022 | Dec 31, 2022 | $6.68M | -21.6% |
| Q3 FY2022 | Sep 30, 2022 | $7.31M | -1.3% |
| Q2 FY2022 | Jun 30, 2022 | $8.63M | +146.8% |
| Q1 FY2022 | Mar 31, 2022 | $7.71M | +214.0% |
| Q4 FY2021 | Dec 31, 2021 | $8.51M | +305.4% |
| Q3 FY2021 | Sep 30, 2021 | $7.41M | +277.2% |
| Q2 FY2021 | Jun 30, 2021 | $3.50M | +66.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.46M | +19.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.10M | +1.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.96M | -24.8% |
| Q2 FY2020 | Jun 30, 2020 | $2.11M | -18.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.06M | +70.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.08M | +295.4% |
| Q3 FY2019 | Sep 30, 2019 | $2.61M | +485.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.59M | +141.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.21M | +26.5% |
| Q4 FY2018 | Dec 31, 2018 | $526.00K | -5.4% |
| Q3 FY2018 | Sep 30, 2018 | $446.00K | -64.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.07M | +13.3% |
| Q1 FY2018 | Mar 31, 2018 | $956.00K | +10.9% |
| Q4 FY2017 | Dec 31, 2017 | $556.00K | -40.2% |
| Q3 FY2017 | Sep 30, 2017 | $1.27M | – |
| Q2 FY2017 | Jun 30, 2017 | $947.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $862.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $930.00K | – |
See a number that looks wrong?